Castle Biosciences Inc. (CSTL)
$33.44
$0.41
(1.24%)
As on 01-Sep-2026 16:00EDT
Market cap
$1,023 Mln
Revenue (TTM)
$357 Mln
P/E Ratio
--
P/B Ratio
2.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0 %
-
ROCE
-- %
-
Industry P/E
44.46
-
EV/EBITDA
43
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
30,549,507
7 Years Aggregate
CFO
$-68.42 Mln
EBITDA
$-183.67 Mln
Net Profit
$-179.64 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
| -14.0 | 19.4 | 58.6 | 39.3 | 18.8 | -15.3 | -- |
|
BSE Sensex*
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
| 46.0 | 23.3 | -8.3 | -45.1 | -36.2 | 95.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
33.4 | 1,023.4 | 357.3 | -19.4 | -5.3 | -4.1 | -- | 2.2 |
| 60.0 | 8,018.1 | 616.9 | -75.1 | 1.7 | -9.3 | -- | 10.2 | |
| 14.2 | 9,638.1 | 6,561.1 | -578.0 | -4.5 | -10.3 | -- | 1.7 | |
| 365.1 | 9,761.6 | 2,589.3 | 222.4 | -6.0 | 3 | 44.5 | 1.3 | |
| 56.0 | 8,696.7 | 3,499.6 | -71.2 | 0.5 | -3.2 | -- | 3.8 | |
| 176.7 | 10,905.5 | 612.8 | -188.1 | -30.6 | -28.1 | -- | 16.4 | |
| 100.9 | 6,577.5 | 1,556.3 | 275.3 | 24.6 | 22.9 | 24.1 | 5.0 | |
| 322.6 | 12,752.7 | 1,504.9 | 160.6 | 13.6 | 10.9 | 79.4 | 8.4 | |
| 170.0 | 9,947.9 | 785.1 | 41.5 | 9.9 | 2 | 251.8 | 4.9 | |
| 29.0 | 12,153.4 | 6,164.0 | 625.0 | 13.0 | 11.8 | 19.9 | 2.4 |
Shareholding Pattern
View DetailsAbout Castle Biosciences (CSTL)
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma,... a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas. Read more
-
Founder, CEO, President & Director
Mr. Derek J. Maetzold
-
Founder, CEO, President & Director
Mr. Derek J. Maetzold
-
Headquarters
Friendswood, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Castle Biosciences (CSTL)
What is the current share price of Castle Biosciences Inc (CSTL) Today?
The share price of Castle Biosciences Inc (CSTL) is $33.44 (NASDAQ) as of 01-Sep-2026 16:00 EDT. Castle Biosciences Inc (CSTL) has given a return of 18.83% in the last 3 years.
What is the current PB & PE ratio of Castle Biosciences Inc (CSTL)?
Since, TTM earnings of Castle Biosciences Inc (CSTL) is negative, P/E ratio is not available.
The P/B ratio of Castle Biosciences Inc (CSTL) is 2.22 times as on 28-Aug-2026, a 41 discount to its peers’ median range of 3.79 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-47.23 |
2.42 |
2024 |
44.11 |
1.77 |
2023 |
-10.19 |
1.50 |
2022 |
-9.26 |
1.56 |
2021 |
-34.70 |
2.64 |
What is the 52 Week High and Low of Castle Biosciences Inc (CSTL)?
The 52-week high and low of Castle Biosciences Inc (CSTL) are Rs 44.28 and Rs 17.72 as of 02-Sep-2026.
What is the market cap of Castle Biosciences Inc (CSTL)?
Castle Biosciences Inc (CSTL) has a market capitalisation of $ 1,023 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Castle Biosciences Inc (CSTL)?
Before investing in Castle Biosciences Inc (CSTL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.